Summary

Thalassemia Treatment Market – Scope of Report
TMR’s report on the global thalassemia treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global thalassemia treatment market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global thalassemia treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the thalassemia treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global thalassemia treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global thalassemia treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global thalassemia treatment market.

The report delves into the competitive landscape of the global thalassemia treatment market. Key players operating in the global thalassemia treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global thalassemia treatment market profiled in this report.

Key Questions Answered in Global thalassemia treatment Market Report
• What is the sales/revenue generated by thalassemia treatment across all regions during the forecast period?
• What are the opportunities in the global thalassemia treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Thalassemia Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global thalassemia treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global thalassemia treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global thalassemia treatment market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Thalassemia Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Thalassemia Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Thalassemia Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017–2031
6.3.1. Blood Transfusion
6.3.2. Chelation Therapy
6.3.3. Bone Marrow Transplantation
6.3.4. Others
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Thalassemia Treatment Market Analysis and Forecast, by Region
7.1. Key Findings
7.2. Market Value Forecast, by Region, 2017–2031
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. Market Attractiveness Analysis, by Region
8. North America Thalassemia Treatment Market Analysis and Forecast
8.1. Introduction
8.2. Key Findings
8.3. Market Value Forecast, by Treatment Type, 2017–2031
8.3.1. Blood Transfusion
8.3.2. Chelation Therapy
8.3.3. Bone Marrow Transplantation
8.3.4. Others
8.4. Market Value Forecast, by Country, 2017–2031
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Treatment Type
8.5.2. By Country
9. Europe Thalassemia Treatment Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Treatment Type, 2017–2031
9.3.1. Blood Transfusion
9.3.2. Chelation Therapy
9.3.3. Bone Marrow Transplantation
9.3.4. Others
9.4. Market Value Forecast, by Country/Sub-region, 2017–2031
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Treatment Type
9.5.2. By Country/Sub-region
10. Asia Pacific Thalassemia Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2017–2031
10.3.1. Blood Transfusion
10.3.2. Chelation Therapy
10.3.3. Bone Marrow Transplantation
10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Treatment Type
10.5.2. By Country/Sub-region
11. Latin America Thalassemia Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2017–2031
11.3.1. Blood Transfusion
11.3.2. Chelation Therapy
11.3.3. Bone Marrow Transplantation
11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Market Attractiveness Analysis
11.5.1. By Treatment Type
11.5.2. By Country/Sub-region
12. Middle East & Africa Thalassemia Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2017–2031
12.3.1. Blood Transfusion
12.3.2. Chelation Therapy
12.3.3. Bone Marrow Transplantation
12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of Middle East & Africa
12.5. Market Attractiveness Analysis
12.5.1. By Treatment Type
12.5.2. By Country/Sub-region
13. Competition Landscape
13.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
13.2. Market Share Analysis, by Company (2022)
13.3. Company Profiles
13.3.1. Bluebird Bio, Inc.
13.3.1.1. Company Overview
13.3.1.2. Product Portfolio
13.3.1.3. SWOT Analysis
13.3.1.4. Financial Overview
13.3.1.5. Strategic Overview
13.3.2. Merck & Co., Inc.
13.3.2.1. Company Overview
13.3.2.2. Product Portfolio
13.3.2.3. SWOT Analysis
13.3.2.4. Financial Overview
13.3.2.5. Strategic Overview
13.3.3. Novartis AG
13.3.3.1. Company Overview
13.3.3.2. Product Portfolio
13.3.3.3. SWOT Analysis
13.3.3.4. Financial Overview
13.3.3.5. Strategic Overview
13.3.4. Celgene Corporation
13.3.4.1. Company Overview
13.3.4.2. Product Portfolio
13.3.4.3. SWOT Analysis
13.3.4.4. Financial Overview
13.3.4.5. Strategic Overview
13.3.5. Takeda Pharmaceuticals Company Limited
13.3.5.1. Company Overview
13.3.5.2. Product Portfolio
13.3.5.3. SWOT Analysis
13.3.5.4. Financial Overview
13.3.5.5. Strategic Overview
13.3.6. Incyte Corporation
13.3.6.1. Company Overview
13.3.6.2. Product Portfolio
13.3.6.3. SWOT Analysis
13.3.6.4. Financial Overview
13.3.6.5. Strategic Overview
13.3.7. Sanofi
13.3.7.1. Company Overview
13.3.7.2. Product Portfolio
13.3.7.3. SWOT Analysis
13.3.7.4. Financial Overview
13.3.7.5. Strategic Overview
13.3.8. Bellicum Pharmaceuticals
13.3.8.1. Company Overview
13.3.8.2. Product Portfolio
13.3.8.3. SWOT Analysis
13.3.8.4. Financial Overview
13.3.8.5. Strategic Overview
13.3.9. GSK plc
13.3.9.1. Company Overview
13.3.9.2. Product Portfolio
13.3.9.3. SWOT Analysis
13.3.9.4. Financial Overview
13.3.9.5. Strategic Overview